课题基金 / 基金详情

Cytokine molecular therapy for intervention of virus infection

Cytokine molecular therapy for intervention of virus infection
干预病毒感染的细胞因子分子治疗
批准号:
18591131
负责人:
KISHIDA Tsunao
金额:
$2.47万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2006
资助国家:
日本
项目状态:
已结题
起止时间:
2006 至 2007

项目摘要

项目成果

KISHIDA Tsunao的其他基金

相似基金

相关文献

中文摘要
翻译
白细胞介素-27 (IL-27)是一种异二聚体细胞因子,由两个多肽亚基il - 27p28和ebv诱导蛋白3 (Ebi3)组成。IL-27信号通过由IL-27R_(WSX-1, TCCR)和gp130组成的异二聚体受体复合物介导,并在包括初始CD4阳性T细胞在内的多种细胞上表达。JAK1/STAT1通路的激活在IL-27R复合物下游的信号转导中起着至关重要的作用。IL-27刺激初始CD4阳性T细胞表达T-bet,随后表达IL-12R62。IL-27依次与IL-12协同诱导Th1免疫应答的启动和维持。IL-27还与IL-12协同诱导干扰素(IFN)-y的产生。最近有研究表明,IL-27以STAT1依赖的方式抑制Th17细胞的产生。综上所述,IL-27参与了Th1承诺的关键步骤,即幼稚的Th前体细胞开始分化为Th1细胞,并且现在认为IL-27与许多人类疾病包括恶性,过敏性和炎症性疾病有关。在本项目中,我们发现IL-27还参与了一种新的病毒感染防御机制。在感染脑心肌炎病毒(EMCV)的C57BI/6小鼠体内转染IL-27基因,分析其寿命。未转染IL-27基因的对照组小鼠在感染后10天内全部死亡,而转染IL-27基因的小鼠在此期间存活率保持100%。为了阐明IL-27抗病毒活性的机制,我们还进行了体外实验,结果强烈提示IL-27直接作用于病毒感染的心肌细胞抑制病毒复制,而诱导获得性免疫反应并不有助于病毒的清除。MDA5介导的途径作为细胞内抗病毒感染的先天机制已被广泛了解,但调控MDA5表达的分子机制尚不清楚。然后我们评估MDA5是否参与il -27介导的病毒抑制。在第16天的小鼠胚胎中建立原代心肌细胞,并用IL-27刺激,导致MDA5 mRNA的剧烈诱导。感染EMCV后,经IL-27处理的细胞在感染后立即大量产生IFN-6,与未经IL-27处理的细胞产生较低水平的IFN形成鲜明对比。通过短干扰RNA对MDA5的特异性沉默完全消除了IL-27激发后心肌细胞中产生的病毒效应。这些发现表明,IL-27信号增强了心肌细胞中MDA5的表达,导致病毒感染触发的MDA5通路增强,进而在感染早期产生I型IFN的强烈诱导,从而有效抑制病毒复制。少
英文摘要
Interleukin-27 (IL-27) is a heterodimeric cytokine composed of two polypeptide subunits, IL-27 p28 and EBV-induced protein 3 (Ebi3). The IL-27 signal is mediated through the heterodimeric receptor complex that consists of IL-27R_(WSX-1, TCCR)and gp130 and is expressed on various cells including naive CD4 positive T cells. Activation of JAK1/STAT1 pathway is crucially involved in the signal transduction downstream of the IL-27R complex. IL-27 provokes naive CD4 positive T cells to express T-bet and, subsequently, IL-12R62. IL-27 sequentially cooperates with IL-12 to induce initiation and maintenance of Th1 immune responses. IL-27 also synergize with IL-12 to induce interferon (IFN)-y production. Recently it was shown that generation of Th17 cells is suppressed by IL-27 in a STAT1 dependent manner. Taken together, IL-27 is involved in the key step for Th1 commitment where naive Th precursor cells commence differentiation into Th1 cells, and it is now considered that IL-27 is associated w … More ith many human diseases including malignant, allergic and inflammatory disorders. In this project, we found that IL-27 is also involved in a novel defense mechanism against virus infection. C57BI/6 mice that had been infected with Encephalomyocarditis virus (EMCV) were transfected in vivo with IL-27 gene, and their longevity was analyzed. All the control mice that received the virus but not IL-27 gene died within 10 days after the infection, whereas survival rate of the IL-27 gene-transfected mice remained 100% during this period. To clarify the mechanism of the anti-virus activity of IL-27, we also performed in vitro experiments, which strongly suggested that IL-27 directly acted on virus-infected cardiomyocytes to suppress virus replication, whereas induction of acquired immune responses did not contribute to the virus clearance. As an intracellular innate machinery against virus infection, MDA5-mediated pathway is widely known, but little is known on molecular mechanisms to regulate MDA5 expression. Then we assessed whether MDA5 participates in the IL-27-mediated virus suppression. Primary cardiac muscle cells were established form the day 16 mouse embryos and stimulated with IL-27, which led to drastic induction of mRNA for MDA5. Infected with EMCV, the IL-27-treated cells showed massive production of IFN-6 immediately after the infection, which was in sharp contrast to the lower level of IFN production by the cells that were not treated with IL-27. Specific silencing of MDA5 by means of the short interfering RNA completely cancelled the and-virus effect that was otherwise produced in cardiomyocytes after the IL-27 provocation. These findings indicate that IL-27 signaling augments expression of MDA5 in cardiac muscle cells, resulting in a strengthening of MDA5 pathway triggered by virus infection, which in turn generates robust induction of type I IFN at an early phase of infection to effectively suppress virus replication. Less
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
lnterleukin-21(lL-21)administration into the nostril alleviates murine allergic rhinitis
将白细胞介素 21 (lL-21) 注入鼻孔可缓解小鼠过敏性鼻炎
DOI: --
发表时间: 2007
期刊: J.Immunol 179(10)
影响因子: --
作者: [Hiromura, Y., et. al.]
通讯作者: et. al.
Interleukin-21 (IL-21) administration into the nostril alleviates murine allergic rhinitis
将白细胞介素 21 (IL-21) 注入鼻孔可缓解小鼠过敏性鼻炎
DOI: --
发表时间: 2007
期刊: J. Immunol 179 (10)
影响因子: --
作者: [Hiromura, Y., T. Kishida, H. Nakano, T. Hama, J. Imanishi, Y. Hisa, O. Mazda]
通讯作者: O. Mazda
DOI: --
发表时间: 2006
期刊: Exp. Clin. Immunol 146(2)
影响因子: --
作者: [Ito, R., M. Shin-Ya, T. Kishida, A. Urano, R. Takada, J. Sakagami, J. Imanishi, M. Kita, Y. Ueda, Y. Iwakura, Keisho, Kataoka, T. Okanoue, O. Mazda]
通讯作者: O. Mazda
IL-21 Triggers both Cellular and Humoral Immune Responses Leading to Therapeutic Antitumor Effects against Head and Neck Squamous Cell Carcinoma.
IL-21 触发细胞和体液免疫反应,从而产生针对头颈鳞状细胞癌的治疗性抗肿瘤作用。
DOI: --
发表时间: 2006
期刊: J.Gene Med. 8(1)
影响因子: --
作者: [Nakano, H., T.Kishida, H.asada, M.Shin-Ya, T.Shinomiya, J.Imanishi, T.Shimada, S.Nakai, M.Takeuchi, Y.Hisa, *O.Mazda]
通讯作者: *O.Mazda
共 18 条
    Establishment of a procedure to eliminate viral sequences by means of the chromosome editing
    • 批准号:
      26670485
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.33万
    • 财政年份:
      2014
    • 负责人:
      KISHIDA Tsunao
    • 依托单位:
    Toward novel molecular targeting strategies for the metabolic syndrome
    • 批准号:
      23591318
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.33万
    • 财政年份:
      2011
    • 负责人:
      KISHIDA Tsunao
    • 依托单位:
    国内基金
    海外基金
    基于CRISPR/Cas9文库筛选蜱传病毒Tamdy virus感染相关宿主因子及其作用机制的研究
    • 批准号:
      --
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      30万元
    • 批准年份:
      2022
    • 负责人:
      周宏
    • 依托单位:
    苹果茎沟病毒(Apple stem grooving virus, ASGV)CP基因介导的RNAi 转基因对ASGV侵染和脱毒的影响研究
    • 批准号:
      31801709
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      21.0万元
    • 批准年份:
      2018
    • 负责人:
      冯超红
    • 依托单位:
    用Sindbis virus系统稳定表达HIV-1病毒样颗粒与抗HIV-1中和抗体诱导
    • 批准号:
      30371317
    • 项目类别:
      面上项目
    • 资助金额:
      20.0万元
    • 批准年份:
      2003
    • 负责人:
      孔维
    • 依托单位: